Jing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Shengmei Zhao
Department of Clinical Laboratory Shandong Provincial Hospital Affiliated to Shandong University Jinan China
2 shared publications- Xiangdong Liu
Department of Clinical Laboratory Shandong Provincial Hospital Affiliated to Shandong University Jinan China
2 shared publications Zhenguo Su
Department of Laboratory Binzhou Medical University Yantai China
2 shared publications- Dajie Zhou
Department of Clinical Laboratory Center, Yantai Yuhuangding Hospital, Yantai, 264099, Shandong, China
1 shared publication Miao Zhang
Department of Clinical Laboratory Shandong Provincial Hospital Affiliated to Shandong University Jinan China
1 shared publicationTing Zhou
Department of Laboratory Chongqing Medical University Chongqing China
1 shared publication
Latest Publications
- Open Access
- 13 May 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (6) , e24467
Development of six immune‐related lncRNA signature prognostic model for smoking‐positive lung adenocarcinoma
Background: Smoking is one of the most hazardous risk factors for the development of lung adenocarcinoma (LUAD). Many survival and prognosis‐related biomarkers were discovered using database mining. However, the precision of immune‐related long noncoding RNAs (lncRNAs) predictions is insufficient. We identified a novel signature to improve the estimate of smoking‐related LUAD prognosis.Methods: The Cancer Genome Atlas database (TCGA) was used to obtain the LUAD lncRNA expression profiles. The smoking‐related LUAD cohort was randomly split into discovery and validation cohorts. To determine the risk score, use the LASSO Cox regression technique on the prognostic immune‐related lncRNA. The risk signature has been developed.Results: A total of 643 immune‐related lncRNAs were identified as potential candidates for a risk signature. Finally, six immune‐related lncRNAs (AL359915.2, AP000695.1, HSPC324, TGFB2‐AS1, AC026355.1, and AC002128.2) were identified and used to carry out risk signature, which showed a close association with overall survival in the discovery cohort. We classified patients as high risk or low risk based on a median risk score of 1.0783. In the discovery cohort, overall survival was marginally longer in the low‐risk group than in the high‐risk category (p = 2.28e08). The area under the curves (AUC) for 1‐, 3‐, and 5‐year survival was 0.67, 0.7, and 0.82, respectively. Furthermore, we successfully validated and combined cohorts using this risk profile. We discovered a strong positive connection between HSPC324 and VIPR1 as a possible novel biomarker for smoking‐related LUAD development in our study.Conclusions: Our research has established a six immune‐lncRNA signature that may be used to predict the prognosis of smoking‐related LUAD with great accuracy.
- 13 May 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (6) , e24467
Open AccessDevelopment of six immune‐related lncRNA signature prognostic model for smoking‐positive lung adenocarcinoma
Background: Smoking is one of the most hazardous risk factors for the development of lung adenocarcinoma (LUAD). Many survival and prognosis‐related biomarkers were discovered using database mining. However, the precision of immune‐related long noncoding RNAs (lncRNAs) predictions is insufficient. We identified a novel signature to improve the estimate of smoking‐related LUAD prognosis.Methods: The Cancer Genome Atlas database (TCGA) was used to obtain the LUAD lncRNA expression profiles. The smoking‐related LUAD cohort was randomly split into discovery and validation cohorts. To determine the risk score, use the LASSO Cox regression technique on the prognostic immune‐related lncRNA. The risk signature has been developed.Results: A total of 643 immune‐related lncRNAs were identified as potential candidates for a risk signature. Finally, six immune‐related lncRNAs (AL359915.2, AP000695.1, HSPC324, TGFB2‐AS1, AC026355.1, and AC002128.2) were identified and used to carry out risk signature, which showed a close association with overall survival in the discovery cohort. We classified patients as high risk or low risk based on a median risk score of 1.0783. In the discovery cohort, overall survival was marginally longer in the low‐risk group than in the high‐risk category (p = 2.28e08). The area under the curves (AUC) for 1‐, 3‐, and 5‐year survival was 0.67, 0.7, and 0.82, respectively. Furthermore, we successfully validated and combined cohorts using this risk profile. We discovered a strong positive connection between HSPC324 and VIPR1 as a possible novel biomarker for smoking‐related LUAD development in our study.Conclusions: Our research has established a six immune‐lncRNA signature that may be used to predict the prognosis of smoking‐related LUAD with great accuracy.
- Open Access
- 31 March 2020
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (8) , e23320
Role of platelet infiltration as independent prognostic marker for gastric adenocarcinomas
Background: In recent years, the relationship between malignant tumors and platelets has been paid more attention. The increase of platelets is an independent risk factor for the poor prognosis of some malignant tumors. Methods: This study retrospectively analyzed the clinical and pathological data of 114 patients with initial gastric cancer from August 2005 to August 2018 in Shandong Provincial Hospital. Single‐factor and multifactor survival analysis were used to evaluate the effect of platelet elevation on postoperative survival. The gastric cancer tissues of the Jinan Central Hospital and its matched paracancerous tissues were collected. The expression of platelets in tissues was detected by immunofluorescence technique. Different numbers of platelets were co‐cultured with MKN‐45 cells, CCK‐8 assay and transwell assay were performed, and the expression of epithelial‐mesenchymal transition‐related proteins was detected. Results: Platelet count was independent factors affecting prognosis. The stratified analysis showed that there was a statistically significant difference in the 5‐year survival rate between the platelet‐increase group and the normal platelet group in the TNM stages I‐II. The expression of platelets in gastric cancer tissues was higher than that in adjacent tissues. The results of CCK‐8 and transwell showed that platelets significantly enhanced the proliferation and metastasis capability of MKN‐45 cells in a concentration‐dependent manner. After co‐culture, the expression level of E‐cadherin protein in MKN‐45 cells decreased, and the protein expression levels of N‐cadherin, vimentin, and VEGFA increased. Conclusion: Platelet elevation is closely related to the occurrence, development, and metastasis of gastric cancer, and platelet count can be used as a prognostic indicator for malignant tumors.
- 31 March 2020
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (8) , e23320
Open AccessRole of platelet infiltration as independent prognostic marker for gastric adenocarcinomas
Background: In recent years, the relationship between malignant tumors and platelets has been paid more attention. The increase of platelets is an independent risk factor for the poor prognosis of some malignant tumors. Methods: This study retrospectively analyzed the clinical and pathological data of 114 patients with initial gastric cancer from August 2005 to August 2018 in Shandong Provincial Hospital. Single‐factor and multifactor survival analysis were used to evaluate the effect of platelet elevation on postoperative survival. The gastric cancer tissues of the Jinan Central Hospital and its matched paracancerous tissues were collected. The expression of platelets in tissues was detected by immunofluorescence technique. Different numbers of platelets were co‐cultured with MKN‐45 cells, CCK‐8 assay and transwell assay were performed, and the expression of epithelial‐mesenchymal transition‐related proteins was detected. Results: Platelet count was independent factors affecting prognosis. The stratified analysis showed that there was a statistically significant difference in the 5‐year survival rate between the platelet‐increase group and the normal platelet group in the TNM stages I‐II. The expression of platelets in gastric cancer tissues was higher than that in adjacent tissues. The results of CCK‐8 and transwell showed that platelets significantly enhanced the proliferation and metastasis capability of MKN‐45 cells in a concentration‐dependent manner. After co‐culture, the expression level of E‐cadherin protein in MKN‐45 cells decreased, and the protein expression levels of N‐cadherin, vimentin, and VEGFA increased. Conclusion: Platelet elevation is closely related to the occurrence, development, and metastasis of gastric cancer, and platelet count can be used as a prognostic indicator for malignant tumors.
- Open Access
- 20 June 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (8) , e22955
Analytical comparison between two hematological analyzer systems: Mindray BC‐5180 vs Sysmex XN‐1000
Background: To compare the Mindray BC‐5180 and Sysmex XN‐1000 instruments by analyzing the results of complete blood count in the external quality assessment in Shandong Province in 2018.Methods: In the external quality assessment, 10 batches of quality control materials were issued throughout the year. The test items were WBC, RBC, Hb, PLT, and HCT. The laboratories using Mindray BC‐5180 and Sysmex XN‐1000 were screened, and the results were analyzed by t test, Passing‐Bablok regression analysis, and Bland‐Altman analysis.Results: Thirty‐six laboratories using Mindray BC‐5180 instruments and thirty‐six laboratories using Sysmex XN‐1000 instruments were screened, and the average difference between the two instruments results is not significant (P > 0.05, t test). Passing‐Bablok regression analysis showed that the 95% confidence interval of the regression equation interception of each test item included 0, and the 95% confidence interval of the slope contained 1, r > 0.98, which showed that the correlation is good. The Bland‐Altman analysis showed that both instruments had more than 95% of the points within the 95% consistency limit (WBC97.2%, RBC95.6%, PLT97.2%, Hb96.7%, HCT97.5%). Within the consistency limit, the absolute value of the difference between the Mindray BC‐5180 instrument and the Sysmex XN‐1000 instrument is WBC 0.14%, RBC 0.26%, PLT 2.7%, and Hb 1.9%. HCT is 0.69%, and the difference is clinically acceptable.Conclusion: It can be considered that the two instruments have good correlation and consistency, and the two instruments can replace each other.
- 20 June 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (8) , e22955
Open AccessAnalytical comparison between two hematological analyzer systems: Mindray BC‐5180 vs Sysmex XN‐1000
Background: To compare the Mindray BC‐5180 and Sysmex XN‐1000 instruments by analyzing the results of complete blood count in the external quality assessment in Shandong Province in 2018.Methods: In the external quality assessment, 10 batches of quality control materials were issued throughout the year. The test items were WBC, RBC, Hb, PLT, and HCT. The laboratories using Mindray BC‐5180 and Sysmex XN‐1000 were screened, and the results were analyzed by t test, Passing‐Bablok regression analysis, and Bland‐Altman analysis.Results: Thirty‐six laboratories using Mindray BC‐5180 instruments and thirty‐six laboratories using Sysmex XN‐1000 instruments were screened, and the average difference between the two instruments results is not significant (P > 0.05, t test). Passing‐Bablok regression analysis showed that the 95% confidence interval of the regression equation interception of each test item included 0, and the 95% confidence interval of the slope contained 1, r > 0.98, which showed that the correlation is good. The Bland‐Altman analysis showed that both instruments had more than 95% of the points within the 95% consistency limit (WBC97.2%, RBC95.6%, PLT97.2%, Hb96.7%, HCT97.5%). Within the consistency limit, the absolute value of the difference between the Mindray BC‐5180 instrument and the Sysmex XN‐1000 instrument is WBC 0.14%, RBC 0.26%, PLT 2.7%, and Hb 1.9%. HCT is 0.69%, and the difference is clinically acceptable.Conclusion: It can be considered that the two instruments have good correlation and consistency, and the two instruments can replace each other.